ACPA, commonly measured with the anti-cyclic-citrullinated peptide 2 (CCP2) tests, are RA-specific autoantibodies and recent functional studies have indicated that they are involved in the causation of RA-associated symptoms (4–8). This evidence concerns the gene AGBL2 and rheumatoid arthritis.